Shows
MedTech Business AcademyMarket Pressures, Medtech Strategy, and Provider Perspectives | Ep 93Market Pressures, Medtech Strategy, and Provider Perspectives In this special two-person episode, Scott Alexander and value analysis leader Barbara Strain discuss the state of medtech commercialization in 2025—from shifting provider priorities to evolving supplier expectations.You’ll hear insight on:Mid-year pressures on provider systems and medtech companiesWhy traditional goals no longer apply—and how to “skate to where the puck is”What manufacturers must do to differentiate in today’s procurement environmentHow KOLs can drive account penetration and peer-based educationThe critical role of supply chain stability, product quality, and ease of trainingWhy full adoption is...2025-07-0320 min
BerlinsideOut32 – Season Finale – The State of Play, The Road Ahead & Where Lies Germany?
Wrapping up season 2 of BerlinsideOut, Ben and Aaron give listeners their take on what to watch out for in international security this summer – particularly at the upcoming NATO Summit in Washington, November’s American election, and the incoming European Commission. The hosts talk about the significance of Kaja Kallas’ nomination as the new EU High Representative for Foreign Affairs and Security Policy and explore the state of German politics after the European Parliament Elections. They also discuss their own highlights of the season, its most important lessons – and give you a taste of what’s next for BerlinsideOut.
Resource...2024-07-0249 minMedTech Business AcademyKOL Management: The Unsung Heroes of Authentic DemandIn this episode of the Med Tech Business Academy, we delve into the pivotal role of Key Opinion Leaders (KOLs) in driving authentic demand within the medtech industry. Skender Daerti, Barbara Strain, and Scott Alexander discuss how influencer marketing has evolved in healthcare, highlighting the importance of managing expectations and effectively utilizing KOLs. Discover strategies for leveraging KOLs to enhance patient outcomes, gain market share, and establish thought leadership. Join us for an insightful conversation on why KOLs are the unsung heroes of medtech innovation.2024-06-2735 min
UfoStation podcasts03e05 - Высшее образование и курсыГость выпуска Григорий Шарцев, Frontend-разработчик в NextCloud, преподаватель на курсах по Vue. Григорий вёл свой курс веб-разработки в университете и 9 лет учит школьников алгоритмам и решению нестандартных задач в лагерях спортивного программирования.2023-11-111h 10UfoStation podcasts03e04 - FAANG, алгоритмы и собеседованияГость выпуска — Виктор Карпов, Software Engineer & Educator: twitter аккаунт, https://twitter.com/vitkarpov; Youtube канал. Алгосики для самых маленьких, https://www.youtube.com/@algoseekee; Coding interviews in a nutshell, https://t.me/coding_interviews2023-07-011h 11UfoStation podcasts03e03 — VitestГости выпускаВладимир Шеремет, разработчик Vitest:- Github аккаунт, https://github.com/sheremet-va;- Twitter аккаунт, https://twitter.com/sheremet_va.2023-05-1052 minUfoStation podcasts03e02 — Медленные и быстрые программыГость выпуска — Андрей Печкуров:- Github аккаунт (https://github.com/puzpuzpuz);- Twitter аккаунт (https://twitter.com/AndreyPechkurov);- Статьи на Medium (https://medium.com/@apechkurov).2023-04-091h 13UfoStation podcasts03e01 — Закрытое женское сообщество QA SistersЭкспериментально социальный выпускГости выпускаОсновательницы закрытого женского сообщества QA Sisters:— Анастасия Заречнева (https://twitter.com/qa_nastasiya)— Юлия Лях (https://twitter.com/sun_in_july)2023-02-281h 10UfoStation podcasts02e08 - Clojure и дорога реальных делГость выпуска — Николай Рыжиков, CTO в компании Health-Samurai (https://www.health-samurai.io/), спикер на конферециях, адепт языка программирования Clojure, активный участник сообществ Clojure, Postgress, FHIR2022-12-031h 53UfoStation podcasts02e07 - Highload между скобокГость выпуска — Григорий Скобелев (https://twitter.com/gskobelevff), Java backend developer, директор программного комитета Podlodka Crew, основатель книжного клуба Между скобок (https://t.me/backend_megdu_skobkah)2022-11-131h 15UfoStation podcasts02e06 - Проникновение в PentestingГость выпуска — Кирилл Curiv (https://t.me/pathsecure), специалист в области информационной безопасности, пентестер в LMSecurity, член сообщества DC7342, privacy исследователь, автор канала @pathsecure (этичные записки из мира InfoSec).
2022-10-011h 19UfoStation podcasts02e05 - Тесты и пицца 🍕Гость выпуска — Дмитрий Тучс (https://t.me/dtuchs), Head of QA at Dodo Engineering; один из преподавателей в https://qa.guru2022-09-121h 48
PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastAlexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted TreatmentGo online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific...2022-08-261h 05
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video PodcastAlexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted TreatmentGo online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific...2022-08-261h 05
PeerView Gastroenterology CME/CNE/CPE Video PodcastAlexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted TreatmentGo online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific...2022-08-261h 05
PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastAlexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted TreatmentGo online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific...2022-08-261h 04
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio PodcastAlexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted TreatmentGo online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific...2022-08-261h 04
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video PodcastAlexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted TreatmentGo online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific...2022-08-261h 05
PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastAlexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted TreatmentGo online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific...2022-08-261h 04
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio PodcastAlexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted TreatmentGo online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific...2022-08-261h 04
PeerView Oncology & Hematology CME/CNE/CPE Video PodcastAlexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted TreatmentGo online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific...2022-08-261h 05
PeerView Gastroenterology CME/CNE/CPE Audio PodcastAlexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted TreatmentGo online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific...2022-08-261h 04
PeerView Internal Medicine CME/CNE/CPE Audio PodcastAlexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted TreatmentGo online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific...2022-08-261h 04
PeerView Internal Medicine CME/CNE/CPE Video PodcastAlexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted TreatmentGo online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific...2022-08-261h 05UfoStation podcasts02e04 - Прогулка по реактивному программированиюГость выпуска — Антон Назаров, iOS разработчик (https://www.youtube.com/channel/UChgyWucAyMDU_Xt9BLBlzrQ, https://twitter.com/M0rtyMerr, https://t.me/m0rtymerr_channel2022-08-011h 00UfoStation podcasts02e03 - Блокчейн, крипта, NFT и DAOГость выпуска — Василиса Версус, CTO at Roketo (https://twitter.com/dcversus, https://www.instagram.com/dcversus)2022-07-272h 27
UfoStation podcasts02e02 - DevOps (февральский выпуск)Гость выпуска — Даниил Кивенко (https://t.me/dkivenko, https://twitter.com/macbet_k), Старший инженер инфраструктуры в Welltory Inc. 2022-04-251h 54
UfoStation podcasts02e01 - IT HealthcareГость выпуска — Александр Павлушкин (https://t.me/pavlushkin_alex, https://www.linkedin.com/in/alexander-pavlushkin/) Software Developer (Healthcare)2022-02-0256 min
UfoStation podcasts01e09 - Менеджеры состоянийГости выпуска — Артем Арутюнян, twitter (https://t.me/artalog), telegram (https://twitter.com/artalar_dev). Александр Колесников, twitter (https://twitter.com/eddartdort)2021-12-291h 11
UfoStation podcasts01e08 - Знакомство с C++ и undefined behaviorГости выпуска Дмитрий Свиридкин (https://twitter.com/Nekrolm), Вячеслав Радько (https://twitter.com/JustSlavic). Путеводитель C++ программиста по неопределенному поведению (https://github.com/Nekrolm/ubbook)2021-11-231h 51
UfoStation podcasts01e07 - WebGL, OpenGL и все-все-всеГости выпуска — контрибьютеры в PixiJS, three.js, babylon.js. Иван Попелышев (https://twitter.com/ivanpopelyshev) и Константин Тимошенко (https://twitter.com/NotUglyFox). Заходите в https://t.me/gamedevforweb для общения с гостями выпуска2021-11-161h 54
UfoStation podcasts01e06 - Функциональная парадигма и HaskellГость выпуска — Денис Шевченко (https://dshevchenko.biz). Моноид в категории эндофункторов (https://www.youtube.com/watch?v=AJy8B6mhRqc). Сайт ruHaskell https://ruhaskell.org). Haskell чат для новичков (https://t.me/haskell_learn).2021-10-171h 40
UfoStation podcasts01e05 - V8. Golang vs NodeJS. Распределенные системы.Гость выпуска — Андрей Печкуров:
- Github аккаунт (https://github.com/puzpuzpuz);
- Twitter аккаунт (https://twitter.com/AndreyPechkurov);
- Статьи на Medium (https://medium.com/@apechkurov).2021-09-271h 18
UfoStation podcasts01e04 - DIY и МикроконтроллерыГость выпуска Сергей Буглаков (https://t.me/redetection) iOS разработчик и DIY maker.
- Patreon, URL: https://www.patreon.com/ReDetection/posts
- Youtube-канал, URL: https://www.youtube.com/channel/UCeXAg7adVy-8aaFnC47ODPQ
- Telegram, URL: https://t.me/ReDetectionMakes2021-09-0729 minUfoStation podcasts01e03 - Яндекс.Браузер, Chromium и разработчикиГости выпуска:
— Константин Крамлих, руководитель в Яндекс.Облаке. В прошлом разработчик в Яндекс.Браузере.
— Вадим Петров, руководитель службы разработки рендеринг-движка Браузера.2021-08-021h 19UfoStation podcasts01e02 - Срезаем верхний слой с TypeScriptГость подкаста Артем Иванов https://t.me/BuggyTheClown, разработчик из Яндекс
Разбирательства Артема в TypeScript:
- TypeScript: unsound behavior или поблажки надежности (https://m.habr.com/ru/post/492106/)
- Strict mode in TypeScript: описание флагов, примеры (https://habr.com/ru/post/490970/)
- Type soundness in TypeScript: the missing part (https://www.youtube.com/watch?v=5j2GrY5HBoI) (видео)2021-06-2835 min
UfoStation podcasts01e01 - Несколько вопросов о NodeJS, JavaScript и TypeScript. TypeChallenge SolutionsГость подкаста Евгений Обрезков — Software Engineer из компании Wix (https://ghaiklor.com/)
В этом выпуске мы поговорим об использовании NodeJS для инфраструктурных задач, JAMStack и NodeJS, отличии работы v8 в nodejs и браузере, ответим на животрепещущий вопрос «JavaScript однопоточный или многопоточный?», поговорим о TypeScript Challenge и TypeScript Challenge Solutions (https://github.com/ghaiklor/type-challenges-solutions), а также многом другом. 2021-06-1342 min
Popcorn Lounge Bonn Rhein SiegStorytelling mit Marketing | Storyteller Florian Hommeyer hat mein Storytelling Strategie verändertWie Sie aus dem vorherigen Storytelling/ Marketing Überschrift ersehen können, geht es nicht nur darum, großartige #Storytelling zu finden, sondern zu verstehen, wie Florian Ihnen helfen kann. Sie können Ihre eigenen tollen Story schreiben und vermarkten. Wenn Sie kein Schriftsteller sind, finden Sie immer noch Inspiration und Einsicht. Ich habe in Blogs und Artikeln einige erstaunliche viele Ideen, Themen gesehen, die von Aldi bis zur Steinzeit in dunkelsten Blogs gelesen. Bis zu den beliebtesten und erfolgreichsten VBlogs von Florian bei LinkedIn reichen. Wenn Sie recherchieren und etwas schreiben möchten, können Sie es tun. Ihr Ziel als Un...2019-11-1825 min
The Effective Statistician - in association with PSIHow to work with key opinion leaders (KOLs)Actionable advise and background information
Click here to find the homepage of the episode.
KOLs play a major role in the health sector and professionally working together with them will boost your career! This episode provides you with lots of insights and tips.
In this episode, we talk
about how the interactions between pharma companies and KOLs look like
which rules are important and how you as a statistician should comply with these
about practical tips of building relationships with KOLs
about opportunities to work with KOLs
and about mindset topics in engaging with...2018-12-1853 min